Relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) carries an extremely poor prognosis, with long-term survival rates of only 10%–20%. The advent of NS7 CAR-T, a novel naturally selected CD7-directed CAR-T therapy that requires no additional genetic modification, has brought a transformative breakthrough to the treatment of these diseases.

At the 2026 Congress of the European Hematology Association (EHA), innovative research from Chinese investigators in the field of multiple myeloma attracted significant attention. The team led by Prof. Wenming Chen from Beijing Chaoyang Hospital, Capital Medical University, presented a series of studies evaluating aponermin (Aponermin)-based combination therapies for multiple myeloma, plasmacytoma, and plasma cell leukemia.

At the 2026 Congress of the European Hematology Association (EHA), Prof. Liang Wang from Beijing Tongren Hospital, Capital Medical University, delivered an oral presentation unveiling the latest follow-up results of CAR2219, a CD19/CD22 dual-target CAR-T cell therapy for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The study reported an impressive 12-month progression-free survival (PFS) rate of 59.8%.

Patients with warm autoimmune hemolytic anemia (wAIHA) have long faced a significant lack of effective second-line treatment options, often becoming trapped in a cycle of corticosteroid dependence and recurrent disease relapse. At the 2026 European Hematology Association (EHA) Congress, Professor Bing Han of Peking Union Medical College Hospital presented the pivotal results of the Phase III ESLIM-02 trial evaluating sovleplenib in wAIHA. The study represents a major breakthrough in a field that has historically lacked targeted therapies and offers new hope for convenient outpatient management of this chronic autoimmune disorder.

The 2026 European Hematology Association (EHA) Congress, held from June 11–14 in Stockholm, Sweden, brought together leading experts from around the world to showcase the latest advances in basic, translational, and clinical hematology.

In June 2026, the European Hematology Association (EHA) Congress officially opened in Stockholm, Sweden, bringing together the global hematology community for one of the field’s most influential scientific events. As the largest and most prestigious annual meeting in hematology, EHA 2026 not only showcased groundbreaking scientific discoveries but also unveiled strategic initiatives that will help shape the future of hematology research and patient care over the next decade.

The 2026 Congress of the European Hematology Association (EHA 2026), held from June 11–14 in Stockholm, Sweden, brought together leading experts from around the world to showcase the latest advances in hematology research, translational medicine, and clinical practice.

At the 2026 Congress of the European Hematology Association (EHA 2026), the team led by Professor Qian Jiang from Peking University People’s Hospital presented several important studies addressing key challenges in chronic myeloid leukemia (CML), including the biological heterogeneity of accelerated-phase disease and predictors of treatment-free remission (TFR).

The 2026 Congress of the European Hematology Association (EHA 2026) was held from June 11 to 14 in Stockholm, Sweden. As one of the most influential international meetings in hematology, EHA brings together leading experts from around the world to showcase the latest advances in basic science, translational research, and clinical practice.

As the 2026 Congress of the European Hematology Association (EHA 2026) prepares to open in Stockholm, Sweden, the global hematology community is once again gathering to share the latest scientific advances and shape the future of blood disease research and treatment.